US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jun 11, 2020 (6 years ago)

Irinotecan HCL Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

What was recalled

Irinotecan HCL Injection, USP, 100mg/5mL, 5 mL vials, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Shiffgraben 23, 38690 Golsar, Germany Distributed by: West-Word Pharmaceutical Corp. Eatontown, NJ 07724 USA, NDC 0143-9583-01

Recalling firm
Hikma Pharmaceuticals USA Inc.
NDC code
0143-9583-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1309-2020

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Irinotecan recalls

See all
Class II · Moderate risk Terminated

Irinotecan Hydrochloride Injection

Reason CGMP Deviations: based on a Warning Letter received by the manufacturer of the recalled product for inadequate out-of specification investigations, complaint and the investigation conclusions.

Areva Pharmaceuticals Inc NDC 59923-714-02 D-0270-2021
Class II · Moderate risk Terminated

Irinotecan HCL Injection

Reason Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

Hikma Pharmaceuticals USA Inc. NDC 0143-9701-01 D-1308-2020
Class II · Moderate risk Terminated

Irinotecan Hydrochloride Injection

Reason Superpotent Drug: High out of specification assay value results for potency.

Ingenus Pharmaceuticals Llc NDC 50742-401-02 D-0891-2018
Class II · Moderate risk Terminated

Irinotecan Hydrochloride Injection

Reason Superpotent Drug: High out of specification assay value results for potency.

Ingenus Pharmaceuticals Llc NDC 50742-402-05 D-0890-2018